12,700 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Purchased by Aristides Capital LLC

Aristides Capital LLC purchased a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 12,700 shares of the biotechnology company’s stock, valued at approximately $168,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of AnaptysBio by 8.4% in the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock valued at $24,411,000 after buying an additional 143,584 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company’s stock valued at $4,428,000 after acquiring an additional 97,200 shares during the period. JPMorgan Chase & Co. increased its stake in shares of AnaptysBio by 240.6% during the 4th quarter. JPMorgan Chase & Co. now owns 114,939 shares of the biotechnology company’s stock worth $1,522,000 after purchasing an additional 81,195 shares during the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after purchasing an additional 43,598 shares during the period. Finally, Point72 Asset Management L.P. lifted its stake in AnaptysBio by 202.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after purchasing an additional 36,300 shares during the last quarter.

AnaptysBio Trading Down 3.9 %

NASDAQ ANAB opened at $17.78 on Tuesday. The company has a market cap of $545.26 million, a price-to-earnings ratio of -2.92 and a beta of -0.09. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $41.31. The company has a 50 day moving average of $17.37 and a 200-day moving average of $21.04.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. On average, equities research analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has approved a stock repurchase plan on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ANAB. Wedbush reissued an “outperform” rating and set a $40.00 price target on shares of AnaptysBio in a research report on Wednesday, February 12th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research note on Monday, March 3rd. JPMorgan Chase & Co. lifted their price objective on shares of AnaptysBio from $36.00 to $42.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Wells Fargo & Company raised their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. Finally, Johnson Rice reaffirmed a “buy” rating on shares of AnaptysBio in a report on Wednesday, March 26th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.11.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.